We just released a special report on the top 10 vaccine companies. We haven’t published this report since 2017, when we only profiled five manufacturers. But five years and one COVID pandemic later, that order has been completely shuffled with many new faces. It’s clear that the vaccine industry is changing fast. In today's episode we'll discuss those global rankings, plus this week's headlines.

To learn more about topics in this episode: 
The top 10 vaccine companies worldwide
Pfizer takes Vyndaqel copay fight to Supreme Court, decrying 'staggeringly overbroad' anti-kickback rule
Atara on verge of landmark approval for first allogeneic T-cell therapy
J&J sets sights on $60B in pharma sales by 2025, targets 8 brands to deliver growth
As FDA rule takes effect, Lucid Hearing launches over-the-counter line of hearing aids

The Top Line is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

We just released a special report on the top 10 vaccine companies. We haven’t published this report since 2017, when we only profiled five manufacturers. But five years and one COVID pandemic later, that order has been completely shuffled with many new faces. It’s clear that the vaccine industry is changing fast. In today's episode we'll discuss those global rankings, plus this week's headlines.
To learn more about topics in this episode: 
<ul>
<li><a href="https://www.fiercepharma.com/pharma/top-10-vaccine-companies-worldwide">The top 10 vaccine companies worldwide</a></li>
<li><a href="https://www.fiercepharma.com/pharma/pfizer-takes-vyndaqel-copay-fight-supreme-court-crying-staggeringly-overbroad-anti-kickback">Pfizer takes Vyndaqel copay fight to Supreme Court, decrying 'staggeringly overbroad' anti-kickback rule</a></li>
<li><a href="https://www.fiercepharma.com/pharma/atara-verge-landmark-approval-first-allogenic-t-cell-therapy">Atara on verge of landmark approval for first allogeneic T-cell therapy</a></li>
<li><a href="https://www.fiercepharma.com/financials/johnson-johnson-sticks-2025-projection-60-billion-pharma-sales-relying-eight-key-brands">J&amp;J sets sights on $60B in pharma sales by 2025, targets 8 brands to deliver growth</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/lucid-hearing-launches-new-over-counter-line-hearing-aids-fda-rule-takes-effect">As FDA rule takes effect, Lucid Hearing launches over-the-counter line of hearing aids</a></li>
</ul>
The Top Line is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement